To complement our battery of St Louis encephalitis (SLE) virus monoclonal antibodies (MAbs), we isolated and characterized MAbs reactive with another member of the SLE virus serocomplex, Murray Valley encephalitis (MVE) virus. From 40 fusion products, we isolated 10 stable hybridomas. The combination of SLE and MVE virus MAbs defined eight epitopes on the MVE envelope (E) glycoprotein. Six of these epitopes (E-la, E-lc, E-ld, E-3, E-4a, E-4b) were identical to those previously demonstrated on SLE virus. Two new epitopes (E-5 and E-6) were also identified. As with SLE virus, the MVE E-lc epitope elicited the most potent virus-neutralizing and protective MAb. Unlike SLE virus, however, one of the cross-reactive epitopes (E-5) elicited neutralizing antibody and protected animals from MVE virus challenge. These results indicate that, while the antigenic domains on viruses within the SLE virus serocomplex are quite similar, epitopes involved in virus neutralization or protection from virus challenge may vary and can be topologically distinct.
The newly defined Flaviviridae family is composed of a number of structurally similar viruses that cause a wide variety of human disease (Porterfield, 1980) . These viruses have three structural proteins: an internal nucleocapsid protein (C), a membrane protein (M), and an envelope (E) glycoprotein (Russell et al., 1980) . Classification using neutralization assays subdivides the family into a number of serocomplexes (Porterfield, 1980; Westaway et al., 1985) . It has long been known that infection with one flavivirus may elicit an immune response that partially protects against challenge with a related flavivirus (Sather & Hammon, 1970; Price & Thind, 1971) . While rapid progress has been made in analysing the antigenic structure of the E glycoprotein for all of the medically important flaviviruses, the antigenic basis for flavivirus cross-protection has not been defined (Heinz, 1986; Roehrig, 1986) . Members of the St LouisMurray Valley-Japanese-West Nile encephalitis virus serocomplex cause lethal encephalitis in weanling mice and adult hamsters following peripheral challenge (Hammon & Sather, 1956; Mathews & Roehrig, 1984) . These viruses are our choice for analysis of flavivirus crossprotection. The nucleic acid sequences and deduced amino acid sequences of the structural protein regions of Murray Valley encephalitis (MVE), St Louis encephalitis (SLE), West Nile encephalitis (WN) and Japanese encephalitis (JE) viruses have recently been published, and the availability of these data makes detailed antigenic comparisons of members of this closely related serocomplex of viruses feasible for the first time (Wengler et al., 1985; Dalgarno et al., 1986; Trent et al., 1987; McAda et al., 1987) .
We have previously studied the antigenic structure of the E glycoprotein of SLE virus using murine monoclonal antibodies (MAbs) elicited by this virus (Roehrig et al., 1983) . We identified 0000-8124 * PRNT and HI reactivities are reported as reciprocal endpoint titres to MVE of MAbs purified and standardized to 100 ktg/ml. eight epitopes that were arranged in a spatial continuum as determined by competitive binding assays. Four of these epitopes were SLE virus-specific, including E-lc which elicited the antibody most efficient at neutralizing virus infectivity and protecting animals from virus challenge (Mathews & Roehrig, 1984) . A similar analysis has been published using JE virus (Kimura-Kuroda & Yasui, 1986; Kobayashi et al., 1984) . Here, we report the isolation of monoclonal antibodies to MVE virus, the identification of the MVE E-glycoprotein antigenic structure, and the comparison of this structure with other members of the MVE-SLE-JE-WN virus serocomplex. We hope to use this information in combination with our previous results with SLE virus as a basis for a detailed study into the mechanism of cross-protection among closely related flaviviruses.
Four-week-old male BALB/c mice were immunized intraperitoneally at 0 and 13 days with 10 to 25 ~tg of purified MVE virus (original strain) in Freund's complete adjuvant. The virus was grown in SW-13 cells and purified by centrifugation on continuous glycerol-tartrate gradients as described previously (Obijeski et al., 1974) . Animals were then bled and tested for anti-MVE virus antibody by ELISA on purified virus antigen. Antibody-positive animals were injected at day 39 with 50 gg virus and used for the preparation of hybridomas 4 days later. Hybridomas were prepared according to Roehrig et al. (1982) , using the non-secreting Sp2/0-Ag-14 myeloma cell line. The fusion products were screened by ELISA. Rabbit anti-MVE virus antibodies or a pool of rabbit anti-MVE, yellow fever (YF) and SLE virus antibodies were diluted 1 : 500 and used to coat 96-well microtitre plates for 1 h at 37 °C or overnight at 4 °C before adding virus antigen in the form of sucrose-acetone-extracted, virus-infected, suckling mouse brain (Tsai et al., 1987) . Hybridoma tissue culture fluid was added, and bound antibody was detected with an anti-mouse IgG conjugated to alkaline phosphatase. Anti-MVE virus secreting hybridomas were cloned in soft agar. Antibody isotype was identified by immunodiffusion as previously described (Roehrig et al., 1982) . The purity of these antibody preparations was characterized by isoelectric focusing (Nicolatti et al., 1979) . Other MAbs used in this study were prepared from animals immunized with SLE virus (Roehrig et al., 1983; Mathews & Roehrig, 1984) . The glycoprotein specificity of the MVE virus MAbs was determined by immunoblotting according to Roehrig & Mathews (1985) with purified MVE virus (data not shown).
Forty uncloned hybridomas were identified and further analysed by antigen capture ELISA on MVE, SLE (strain 77V12908) and YF (strain 79H327-Gambia) viruses to establish their antigenic cross-reactivities. Of the 40 MAbs identified, 15 were MVE virus-specific, three reacted with MVE and SLE viruses, one reacted with MVE and YF viruses and 21 were crossreactive with all three viruses. Eight hybridomas with distinct binding characteristics were eventually isolated and cloned (Table 1) . Reactivity of these antibodies in ELISA was subsequently tested on a larger battery of antigens including those from JE (G 8924), WN (Egyptian 101), Alfuy (ALF; MRM 3929), Kunjin (KUN; MRM 16), dengue type 1 (DEN; Hawaii) and Venezuelan equine encephalomyelitis (VEE; TC-83) viruses. These hybridomas demonstrated specificities ranging from MVE virus type-specific to flavivirus group-reactive. Epitopes were subsequently defined on the basis of antigenic cross-reactivity and serological activity in plaque reduction neutralization tests (PRNT) and haemagglutination-inhibition (HI) assays. For the biological assays, the antibodies were purified from ascitic fluids by ammonium sulphate precipitation and Protein A-Sepharose column chromatography, and standardized to 100 Bg/ml (Ey et al., 1978) . Isoelectric focusing showed that the major antibody present was that of the hybridoma. Neutralization activity was quantified in a PRNT assay using 50 to 100 p.f.u. per test (Roehrig et al., 1983) seventy percent endpoints were determined. Haemagglutinationinhibition assay titres were determined using 4 to 8 units of sucrose-acetone-extracted virusinfected mouse brain antigen at pH 6.4 to 6.6 (Roehrig et al., 1983) . Eight epitopes were identified. MVE virus epitope nomenclature was based on our previously published epitope designations with SLE virus. MVE virus epitopes demonstrating ELISA, HI and PRNT reactivities identical to those found with SLE virus were assigned identical names. Three of these epitopes (E-la, E-lc, and E-ld) were type-specific for MVE virus, as demonstrated by their lack of reactivity with the other closely related Australian flaviviruses (Table 1) . One epitope was shared by MVE and JE viruses (E-5). One epitope was shared by MVE, JE and ALF viruses (E-6). Two epitopes were flavivirus group-reactive (E-4a and E-4b). The remaining epitope (E-3) was identified by the SLE virus MAb, 2B5B-3 (Roehrig et al., 1983) . Of these epitopes, E-lc, E-ld, E-3, E-4b and E-5 elicited MVE virus-neutralizing antibody (Table 1) . HI activity was associated with MAbs that defined the E-lc, E-3, E-4b and E-6 epitopes (Table 1) .
To analyse the ability of these MAbs to protect animals from a peripheral challenge with MVE virus, various quantities of MAbs purified from ascitic fluid were diluted in phosphatebuffered saline and injected into the tail vein of 21-day-old Swiss outbred mice, 24 h before intraperitoneal (i.p.) challenge with 500 i.p. LD5o of MVE virus. An!mals were monitored for 14 days. Anti-E-lc MAb was most efficient at protecting the animals, requiring as little as 0.1 p~g to protect 50~o of challenged animals ( Table 2) . The subcomplex MAb, anti-E-5, was also protective but not as efficient as anti-E-lc MAb. Presumably, as with other SLE virus MAbs, the protective capacity of anti-E-5 MAb could be attributed to its ability to neutralize virus infectivity (Table 1) ; however, a surprising result was the protective capacity of anti-E-la and anti-E-6 MAbs, in view of the fact that neither MAb could neutralize virus infectivity in vitro. Anti-E-la MAb was actually the second most efficient protective antibody tested, requiring only 5 Ixg to protect 100~ of challenged animals. Anti-E-la SLE virus MAb (3B4C-7) protected 40~o of animals that received 200 ~tg (Mathews & Roehrig, 1984) .
These results corroborate the close antigenic relationship between viruses of the SLE virus serocomplex. Only the E-lb epitope (HI-positive, PRNT-negative) was not identified on MVE virus. This could be due to our failure to isolate the appropriate MAb or to an absence of the Short communication epitope. A critical neutralization domain defined by an anti-E-lc MAb exists on both MVE and SLE viruses, and anti-E-Ic MAbs protect animals from challenge with these viruses. One clear but unexplained difference between these two viruses is that non-neutralizing anti-El a MAb protects animals from MVE but not SLE virus challenge. Non-neutralizing MAbs also appear to protect animals from YF virus infection (Gould et al., 1986) . In that study, MAbs were transferred in the form of crude ascitic fluid, making actual quantifiable interpretations of the results difficult. A similar study with YF virus using purified MAbs confirmed the ability of non-neutralizing MAbs to protect from YF virus challenge (Brandriss et al., 1986) . In both cases, however, the challenge model was intracerebral inoculation of baby mice. The relevance of that system to a true viscerotropic YF virus infection has not been documented. No experiments were done in either study to determine the mechanism of protection of these non-neutralizing MAbs. As suggested previously, MVE virus appears to be most closely related to JE virus (Kimura-Kuroda & Yasui, 1986 ). This is not surprising since these two viruses occur in Australia and Asia, respectively. Of the eight epitopes identified, the five studied here (E-3, E-4a, E-4b, E-5 and E-6) and one more epitope occurring on the E glycoprotein of SLE virus (E-2) are shared by one or more members of the serocomplex. Although MVE and SLE viruses demonstrated a very similar antigenic structure, these results appear to define differences in virus neutralization and protection epitopes. Anti-E-3 MAb did not neutralize SLE virus, but it did neutralize MVE virus in vitro. Two other cross-reactive epitopes (E-5 and E-6) elicited antibody that protected a proportion (30 to 40~) of animals from MVE virus challenge. No cross-reactive MAbs efficiently protected animals from SLE virus challenge when 5 ~tg of MAb was used (Mathews & Roehrig, 1984 ). An attempt to correlate biological activity and spatial location of epitopes to protection from cross-challenge with SLE, MVE and JE viruses is being made.
